



TRIPES.23AUS2C1

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


Applicant : Sällberg, et al.  
Appl. No. : 10/817,591  
Filed : April 2, 2004  
For : VACCINES CONTAINING  
RIBAVIRIN AND METHODS OF  
USE THEREOF  
Examiner : Li, Bao Q.  
Group Art Unit : 1648

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 10, 2006

(Date)

  
Eric S. Furman, Reg. No. 45,664

**INTERVIEW SUMMARY**

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

The attached interview summary reflects the substance of the personal interview held between Examiner Li, Supervisor Campell and the undersigned on May 16, 2006.

Appl. No. : 10/817,591  
Filed : April 2, 2004


### SUMMARY OF INTERVIEW

Applicants wish to thank Examiner Li and Supervisor Campell for the courtesy extended during the personal interview held on May 16, 2006. During the interview between the undersigned, Examiner Li and, Supervisor Campell, the restriction requirement, the claim objections, the enablement rejections under 35 U.S.C. § 112, first paragraph, the new matter rejections under 35 U.S.C. § 112, first paragraph, the provisional double patenting rejection, and the rejections under 35 U.S.C. § 103 raised in the Office Action mailed February 27, 2006 were discussed. The undersigned and the Examiner agreed to the following: (1) Claims 36-38, 42-53, and 57-65 are linking claims and will be examined in the subject application. (2) Claims 66-73 and 74-81 would be amended such that Claims 67-73 and Claims 75-81 properly depend from Claims 66 and 74, respectively, and the objection to the claims would be withdrawn. (3) Applicants agreed to submit a declaration demonstrating that those of skill in the art at the time of filing the subject application understood that fragments of NS3/4A as small as 8 amino acids are immunogenic, which would overcome the enablement rejection with respect to the use of such fragments. (4) The new matter rejections would be withdrawn in view of Applicants' disclosure. (5) The double patenting rejection would be overcome by submitting an appropriate terminal disclaimer. (6) The obviousness rejections would be withdrawn in light of the fact that the cited references, *i.e.*, Hultgren et al., Encke et al. and Tam, do not make obvious the claimed invention alone or in combination.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 10, 2006

By:   
Eric S. Furman  
Registration No. 45,664  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

Please Direct All Correspondence to Customer Number **20995****AMENDMENT / RESPONSE TRANSMITTAL**

Applicant : Sällberg, et al.  
App. No : 10/817,591  
Filed : April 2, 2004  
For : VACCINES CONTAINING  
RIBAVIRIN AND METHODS OF USE  
THEREOF  
Examiner : Li, Bao Q.  
Art Unit : 1648

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 10, 2006

(Date)

Eric S. Fulman, Ph.D., Reg. No. 45,664

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

- (X) Amendment and Response to Office Action in twenty (20) pages.
- (X) Declaration Under 37 C.F.R. § 1.132 in two (2) pages with attached PCT publications.
- (X) Interview Summary in two (2) pages.
- (X) Terminal Disclaimer in two (2) pages with attached assignments in three (3) pages.

The fee has been calculated as shown below:

The present application qualifies for Small Entity Status under 37 CFR 1.27.

FEE CALCULATION				
FEE TYPE		FEE CODE	CALCULATION	TOTAL
Excess Claims	52 46 6	2202 (\$25)	6 x 25 =	\$150
Excess Independent	2- 2= 0	2201 (\$100)	0 x 100 =	\$0
1 Month Extension	1.17(a)(1)	2251 (\$60)		\$60
			<b>TOTAL FEE DUE</b>	<b>\$210</b>

- (X) A check in the amount of \$210 is enclosed.
- (X) Return prepaid postcard.

Docket No.: TRIPEP.23AUS2C1

July 10, 2006


App. No.: 10/817,591

Page 2 of 2

**Please Direct All Correspondence to Customer Number 20995**

---

- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.



---

Eric S. Fulman, Ph.D.  
Registration No. 45,664  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

2632858 sma052606